ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för tivozanib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

30 träffar

Bibliografisk träff 2024-07-01

Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.

Johns AC, Campbell MT, Gao M, Hahn AW, Lim Z, Wang E, Gao J, Shah AY, Msaouel P, Tannir NM.

Oncologist · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1093/oncolo/oyae037

Bibliografisk träff 2024-05-01

Tivozanib-induced activation of the mitochondrial apoptotic pathway and suppression of epithelial-to-mesenchymal transition in oral squamous cell carcinoma.

Choi NE, Park SC, Kim IR.

Korean J Physiol Pharmacol · research-article; journal article · DOI 10.4196/kjpp.2024.28.3.197

Bibliografisk träff 2024-03-01

Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.

Beckermann KE, Asnis-Alibozek AG, Atkins MB, Escudier B, Hutson TE, Kasturi V, McDermott DF, Pal SK, Porta C, Rini BI, Verzoni E.

Oncologist · research support, non-u.s. gov't; research-article; journal article · DOI 10.1093/oncolo/oyad348

Bibliografisk träff 2023-11-22

Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis.

Chen YC, Chen JH, Hsieh FI.

J Chin Med Assoc · research support, non-u.s. gov't; research-article; systematic review; network meta-analysis; journal article · DOI 10.1097/jcma.0000000000001026

Bibliografisk träff 2023-10-01

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.

Barata PC, Chehrazi-Raffle A, Allman KD, Asnis-Alibozek A, Kasturi V, Pal SK.

Oncologist · clinical trial, phase ii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1093/oncolo/oyad132

Bibliografisk träff 2023-09-07

Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis.

Krawczyk K, Śladowska K, Holko P, Kawalec P.

Front Pharmacol · review-article; review; journal article · DOI 10.3389/fphar.2023.1223929

Bibliografisk träff 2023-06-07

Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis.

Heseltine J, Allison J, Wong S, Prasad K, Oong ZC, Wong H, Law A, Charnley N, Parikh O, Waddell T, Chow S.

Target Oncol · multicenter study; journal article · DOI 10.1007/s11523-023-00972-8

Bibliografisk träff 2023-04-26

HPLC methods for studying pharmacokinetics of tivozanib and in vitro metabolic interaction with dexamethasone in rat.

Zayed AL, Hamadneh GN, Hroot JA, Mayyas A, Jaber SA, Qinna NA.

J Pharm Biomed Anal · journal article · DOI 10.1016/j.jpba.2023.115423

Bibliografisk träff 2023-04-04

Efficacy and Safety of Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma: A Systematic Review of Clinical Trials.

Farrukh M, Ali MA, Naveed M, Habib R, Khan H, Kashif T, Zubair H, Saeed M, Butt SK, Niaz R, Garg I, Fatima A, Aiman W.

Hematol Oncol Stem Cell Ther · systematic review; journal article · DOI 10.56875/2589-0646.1027

Bibliografisk träff 2023-03-02

Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma.

Sakellakis M, Zakopoulou R.

Cureus · review-article; review; journal article · DOI 10.7759/cureus.35675

Bibliografisk träff 2023-03-01

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.

Meza L, McDermott DF, Escudier B, Hutson TE, Porta C, Verzoni E, Atkins MB, Kasturi V, Pal SK, Rini B.

Oncologist · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article · DOI 10.1093/oncolo/oyac255

Bibliografisk träff 2023-02-14

Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model.

Alanazi WA, Alanazi AS, El-Nagar DM, Aljuraybah AM, Alsanea S, Alharbi M.

Pharmaceuticals (Basel) · research-article; journal article · DOI 10.3390/ph16020295

Bibliografisk träff 2023-01-01

Tivozanib: A New Hope for Treating Renal Cell Carcinoma.

Passi I, Billowria K, Kumar B, Chawla PA.

Anticancer Agents Med Chem · review; journal article · DOI 10.2174/1871520622666220617103126

Bibliografisk träff 2022-12-01

A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE).

Mahmood S, Li D, Lee A, Rowe J, Beg M, Kasturi V, Iyer R, Abrams T, Dayyani F.

Future Oncol · clinical trial protocol; journal article · DOI 10.2217/fon-2022-0844

Bibliografisk träff 2022-11-18

Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial.

Ramnaraign BH, Lee JH, Ali A, Rogers SC, Fabregas JC, Thomas RM, Allegra CJ, Sahin I, DeRemer DL, George TJ, Chatzkel JA.

Future Oncol · review; journal article · DOI 10.2217/fon-2022-0392

Bibliografisk träff 2022-08-23

Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer.

Zengin ZB, Pal SK, McDermott DF, Escudier B, Hutson TE, Porta C, Verzoni E, Atkins MB, Kasturi V, Rini B.

Clin Genitourin Cancer · randomized controlled trial; journal article · DOI 10.1016/j.clgc.2022.08.005

Bibliografisk träff 2022-08-02

Initial research on the effect and mechanism of Tivozanib on pulsed dye laser induced angiogenesis.

Wang B, Zhang Y, Lou Y, Hu X, Li F.

Lasers Surg Med · journal article · DOI 10.1002/lsm.23586

Bibliografisk träff 2022-07-25

Tivozanib for the treatment of advanced renal cell carcinoma.

Chatzkel J, Ramnaraign B, Sonpavde G.

Expert Opin Pharmacother · journal article · DOI 10.1080/14656566.2022.2102419

Bibliografisk träff 2022-06-17

Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval.

Viray H, McDermott DF, Einstein DJ.

Expert Rev Anticancer Ther · review; journal article · DOI 10.1080/14737140.2022.2088515

Bibliografisk träff 2020-07-21

Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma.

Jacob A, Shook J, Hutson TE.

Future Oncol · review; journal article · DOI 10.2217/fon-2020-0443

Bibliografisk träff 2018-03-20

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.

Molina AM, Hutson TE, Nosov D, Tomczak P, Lipatov O, Sternberg CN, Motzer R, Eisen T.

Eur J Cancer · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1016/j.ejca.2018.02.009

Bibliografisk träff 2013-12-03

Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP).

Yang D, Kathawala RJ, Chufan EE, Patel A, Ambudkar SV, Chen ZS, Chen X.

Future Oncol · research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; journal article · DOI 10.2217/fon.13.253

Bibliografisk träff 2013-05-28

Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.

Fishman MN, Srinivas S, Hauke RJ, Amato RJ, Esteves B, Cotreau MM, Strahs AL, Slichenmyer WJ, Bhargava P, Kabbinavar FF.

Eur J Cancer · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1016/j.ejca.2013.04.019

Bibliografisk träff 2013-04-11

Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer.

Wolpin BM, Ng K, Zhu AX, Abrams T, Enzinger PC, McCleary NJ, Schrag D, Kwak EL, Allen JN, Bhargava P, Chan JA, Goessling W, Blaszkowsky LS, Supko JG, Elliot M, Sato K, Regan E, Meyerhardt JA, Fuchs CS.

Oncologist · clinical trial, phase ii; brief-report; multicenter study; journal article · DOI 10.1634/theoncologist.2012-0378

Bibliografisk träff 2013-01-01

Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).

Haberkorn BC, Eskens FA.

Future Oncol · review; journal article · DOI 10.2217/fon.12.167

Bibliografisk träff 2012-10-18

Re: Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.

Taneja SS.

J Urol · comment; journal article · DOI 10.1016/j.juro.2012.08.170

Bibliografisk träff 2012-09-17

Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors.

McTigue M, Murray BW, Chen JH, Deng YL, Solowiej J, Kania RS.

Proc Natl Acad Sci U S A · research support, non-u.s. gov't; research-article; journal article · DOI 10.1073/pnas.1207759109

Bibliografisk träff 2012-04-09

Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.

Nosov DA, Esteves B, Lipatov ON, Lyulko AA, Anischenko AA, Chacko RT, Doval DC, Strahs A, Slichenmyer WJ, Bhargava P.

J Clin Oncol · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1200/jco.2011.35.3524

Bibliografisk träff 2011-10-05

Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.

Eskens FA, de Jonge MJ, Bhargava P, Isoe T, Cotreau MM, Esteves B, Hayashi K, Burger H, Thomeer M, van Doorn L, Verweij J.

Clin Cancer Res · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-11-0411

Bibliografisk träff 2010-09-01

Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors.

De Luca A, Normanno N.

IDrugs · review; journal article